0000950170-24-041527.txt : 20240403
0000950170-24-041527.hdr.sgml : 20240403
20240403204743
ACCESSION NUMBER: 0000950170-24-041527
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Noonberg Sarah B.
CENTRAL INDEX KEY: 0001706301
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41949
FILM NUMBER: 24821261
MAIL ADDRESS:
STREET 1: 331 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Metagenomi, Inc.
CENTRAL INDEX KEY: 0001785279
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813909017
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5959 HORTON STREET
STREET 2: 7TH FLOOR
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 871-4880
MAIL ADDRESS:
STREET 1: 5959 HORTON STREET
STREET 2: 7TH FLOOR
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: Metagenomi Technologies, LLC
DATE OF NAME CHANGE: 20190812
4
1
ownership.xml
4
X0508
4
2024-04-01
0001785279
Metagenomi, Inc.
MGX
0001706301
Noonberg Sarah B.
C/O METAGENOMI, INC.
5959 HORTON STREET, 7TH FLOOR
EMERYVILLE
CA
94608
false
true
false
false
Chief Medical Officer
false
Common Stock
2024-04-01
4
A
false
57763
0.00
A
100374
D
Stock Option (Right to Buy)
10.82
2024-04-01
4
A
false
242875
0
A
2034-03-31
Common Stock
242875
242875
D
These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
/s/ Matthew L. Wein, attorney-in-fact
2024-04-03